NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Medical Devices · USD

Globus Medical, Inc. (GMED) Stock Analysis

Globus Medical, Inc. (GMED) is a Medical Devices stock listed on NYSE and quoted in US Dollar.

GMED

$78.29

+$0.17 (+0.22%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GMED with… →

GMED Key Statistics

As of Sep 4, 2026
Trading
Open
$77.23
Previous Close
$78.12
Day's Range
77.07–78.69
52-Week Range
54.15–101.40
Volume
1.12M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.96
Valuation
Market Cap
$10.51B
P/E Ratio
20.02
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
14.50
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.49
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.34
EPS (ttm)Profit attributable to each share over the last twelve months.
3.91
Financials (FY)
Revenue (FY)
$2.94B+16.65%
Net Income (FY)
$537.87M+422.28%
Profit marginThe share of revenue left as profit after all costs and taxes.
17.03%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
111.83M
1-Year Return
+29.86%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
1.59M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

GMED Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−10.33%
2025+5.56%
2024+55.21%
2023−28.25%
2022+2.87%
2021+10.70%
2020+10.77%
2019+36.04%
2018+5.30%
2017+65.66%
2016 (partial year)+6.85%

As of September 4, 2026.

GMED Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.94B$537.87M18.3%
2024$2.52B$102.98M4.1%
2023$1.57B$122.87M7.8%
2022$1.02B$190.17M18.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.94B$1.98B$537.19M$537.87M18.3%
2024$2.52B$1.48B$219.39M$102.98M4.1%
2023$1.57B$1.02B$201.42M$122.87M7.8%
2022$1.02B$759.12M$236.25M$190.17M18.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

GMED Valuation vs Medical Devices Median

Median of 151 stocks
MetricGMEDMedical Devices medianvs median
P/E20.0226.8025% below
P/S ratio3.342.9812% above
Profit margin17.03%−1.69%18.7 pts above

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Globus Medical, Inc. (GMED) at $10.51B. It is classified in the Medical Devices industry, within the Healthcare sector. The company reports 6,000 employees.

GMED last closed at $78.29 on September 4, 2026. That is +$0.17 (+0.22%) against the previous close. Over the past 52 weeks the price has ranged from $54.15 to $101.40. The latest close sits 44.58% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $2.94B. Against the prior fiscal year total of $2.52B, that is a change of +16.65%. Net income for the same year was $537.87M. That is +422.28% against the prior fiscal year. Profit margin runs at 17.03%. That is 18.7 percentage points above the Medical Devices median of −1.69%. Trailing earnings per share are 3.91.

Across the 4 fiscal years on file, revenue moves from $1.02B in 2022 to $2.94B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 20.02 times earnings. That is 25.3% below the Medical Devices median of 26.8. On forward earnings the ratio is 14.5. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.49. The price-to-sales ratio is 3.34. On price-to-sales that is 12.31% above the Medical Devices median of 2.98. 151 Medical Devices companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +29.86%. Across 10 years the annualized return works out at +12.57%. Beta against the wider market is reported at 0.96. Annualized volatility over the trailing 10 years is 35.5%.

Growth & Income

No dividend is on file for GMED.

So far in 2026 the price is −10.33%. Across the complete calendar years on file, 2017 returned +65.66% and 2023 returned −28.25%. Of the 9 complete calendar years on file, 8 finished higher.

Peer Comparison

Globus Medical, Inc. (GMED) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Globus Medical, Inc. GMED $10.51B 20.0
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Globus Medical, Inc. trades at a P/E of 20.0.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Globus Medical, Inc.

Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives. It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies; hip and knee arthroplasty solutions, including modular cement and cementless hip stems, acetabular cups, femoral heads, highly cross-linked liners, partial knee systems, cruciate retaining, posterior stabilized, and revision options; spinal cord stimulation services; and neuromonitoring services, which provide onsite and remote monitoring of the neurological systems. In addition, the company offers ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative and image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cells, tissues, and cellular and tissue-based products. The company sells its products through direct and distributor sales representatives; and independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Visit website →